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Abstract
Background and Objectives: Tumor necrosis factor-a (TNF-a) plays a very important role in the development and progress
of cancer. Some TNF-a polymorphisms have been confirmed to increase cancer risks; however, the association between
TNF-a-238 polymorphism and cancers remains controversial and ambiguous. The aim of this study is to explore a more
precise estimation of its relationship with cancer using meta-analysis.
Methods: Electronic searches of several databases were conducted for all publications on the association between this
variant and cancer through March 2011. Odds ratios (OR) with 95% confidence intervals (95% CI) were used to access the
strength of this association in the random-effect model.
Results: Thirty four studies with 34,679 cancer patients and 41,186 healthy controls were included. This meta-analysis
showed no significant association between TNF-a-238 polymorphism and cancers (AA+GA vs GG: OR=1.09, 95%CI=0.88–
1.34). In Caucasian and Asian subgroups, OR values (95% CI) were 1.14 (0.91–1.43) and 0.97 (0.58–1.61), respectively. In the
subgroups of cancer type, no significant association was detected. The sensitivity analysis further strengthened the validity
of these negative associations. No publication bias was observed in this study.
Conclusions: No significant association was found between the TNF-a-238 polymorphism and the risk for cancer.
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Introduction
Tumor necrosis factor-a (TNF-a) is the most important pro-
inflammatory cytokine involved in the growth, differentiation,
cellular function andsurvival of manycells. Itis produced by diverse
kinds of cells, such as macrophages, neutrophils, fibroblasts,
keratinocytes, NK cells, T and B cells, and tumor cells [1]. TNF-
a has been reported to play an important role in the pathogenesis of
cancer [2].
As transcription of TNF-a is regulated under genetic control,
recent studies [3–5] have shown that its promotor polymorphisms at
2238 (rs361525), 2308 (rs1800629), 2857 (rs1799724), and 21031
(rs1799964) positions could regulate TNF-a production. TNF-a-308
polymorphism has been confirmed as a risk factor for a range of
cancers by meta-analysis, such as breast, gastric and hepatocellular
cancers[6–8].Jangetal[9]reportedthatTNF-a-238polymorphism
might play an apparently protective role against cancers. And many
studieshave focused on the relation of thispolymorphism todifferent
types of cancer [4,9–41]. However, an apparent discrepancy existed
in the results. For the currently published studies only refer to a
modest sample size and unified ethnicity, each of them might not
achieve a reliable conclusion. Thus, we conducted this meta-analysis
to combine the available studies [42].
Publication search
Electronic databases (PubMed, EMBase, Cochrane Central
Register of Controlled Trials and ISI Web of Science) were
searched for all publications on the association between TNF-a-
238 polymorphism and cancer through March 2011. The
keywords were as follows: cancer/carcinoma, polymorphism/
variant/genotype/SNP, and tumor necrosis factor/TNF-a. All the
references of retrieved articles were also included as additional
studies in this study. All the studies must meet the following
criterias: (1) case-control study; (2) the outcome had to be cancer;
and (3) at least two comparison groups (cancer group vs. control
group).
Data extraction
This meta-analysis included a total of 34 articles on TNF-a-
238 and cancer. Two authors extracted the data independently
and in duplicate. Items of the author’s last name, year of
publication, country of origin, source of the study population,
genotypes and numbers of cases and controls and TNF-a
genotyping method were extracted. The results were compared,
disagreements were discussed, and consensus was reached.
MOOSE Checklist and flow chart for the studies were shown
as Checklist S1 and Figure S1.
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Review manager 5.0 was used to perform meta-analysis for
TNF-a-238 polymorphisms (AA+GA versus GG genotype). The
crude odds ratios (OR) and 95% CI were estimated for each study
in a fixed- or random-effect model Heterogeneity among studies
were examined with I
2 statistic interpreted as the proportion of
total variation contributed by between-study variation. If there was
a statistical difference in terms of heterogeneity (P,0.05), a
random-effect model was selected to pool the data. A fixed-effect
model, otherwise, was employed. Relative influence of each study
on the pooled estimate was assessed by omitting one study at a
time for sensitivity analysis. Funnel plots were used to evaluate
publication bias. All P-values were two-tailed.
Results
In this article, the association of TNF-a-238, 2308 with cancer
risk was investigated using meta-analysis in a range of populations.
A total of 34 studies were identified to evaluate the relationship
between TNF-a-238 polymorphism and risk for cancer. The
detailed characteristics of the studies were shown in Table S1.
34,679 cancer patients and 41,186 healthy controls were included
in this study. There were 9 studies for gastric cancer, 3 studies for
breast cancer, 2 studies for lung cancer, 4 studies for hepatocellular
carcinoma, 2 studies for myeloma, 2 studies for cervical cancer, 2
studies for oral cancer, 2 studies for prostate cancer, 2 studies for
lymphoma and 5 studies for other 5 different cancers. Among
those 34 studies, there were 16 Caucasus and 18 Asian studies,
respectively.
As shown in Table 1, the OR for cancers (95% CI) in overall
studies with AA+AG vs GG of TNF-a-238 polymorphism was
1.09 (0.88–134, P=0.42) (Table. 1). In Caucasian and Asian
populations, ORs (95% CI) were 1.14 (0.91–1.43) and 0.97 (0.58–
1.61), respectively. When stratified by the cancer type, the OR
(95% CI) for gastric cancer was 1.22 (0.88–1.70) and for breast
cancer being 1.13 (0.77–1.67); and similarly, values were 1.44
(0.82–2.52) and 0.99 (0.66–1.50) for hepatocellular carcinoma and
other cancers. The forest plots of the meta-analysis were shown in
Fig. 1.
Furthermore, according to the analysis, we found that there was
evidence of heterogeneity in the association between TNF-a-238
polymorphism and risk for cancers among the overall 34 and
stratified studies: I
2=77% in overall populations, I
2=75% in
Caucasus populations and I
2=79% in Asian populations. A
random-effect model was employed in the ORs calculation. To
further strengthen our findings, we conducted the sensitivity
analysis. In the sensitivity analysis, there was little modification of
the estimates after exclusion of individual study, with pooled ORs
ranging from 1.02 to 1.13 for TNF-a-238 polymorphism.
The shape of the funnel plots was prone to be symmetrical,
suggesting that there was no evidence of publication bias among
the studies (Fig. 2). The results of this meta-analysis leaded to our
conclusion that no significant association was manifested between
TNF-a-238 polymorphism and the risk for cancers.
Discussion
As inflammation has been assumed as a key factor involving in
the pathogenesis of cancer, TNF-a, the most crucial inflammatory
cytokine, has been implicated in both the development and
progression through pathways of ‘‘the NF-kB and AP-1 transcrip-
tion factor complexes activation’’ in experimental and human
cancer studies [2,9]. Because A allele of TNF-a at 2238 in the
promoter region was found to down-regulate gene expression
[5,22], studies on the relationship between this variant and cancers
has been extensively investigated during recent decades [4,9–41].
However, results from these studies were ambiguous. To further
provide insights into this debated subject, a meta-analysis is
needed to achieve a more reliable and comprehensive conclusion.
To the best of our knowledge, we used meta-analysis to
investigate the association between TNF-a-238 polymorphism and
risk of cancers for the first time. With 34,679 cancer patients and
41,186 healthy controls included, this study had a greater power
than all previous ones. We did not detect any significant
association between TNF-a-238 polymorphism and cancer
susceptibility in the overall population, with summary OR being
1.09 (0.88–1.34). Subgroup analyses stratified according to
ethnicity and cancer type were also preformed, whilst with
negative results acquired.
Because heterogeneity was found among the studies of overall
and subgroups, random-effect model could be introduced to our
analysis. Then, a sensitivity analysis was performed by removing
one study for each time and re-running the model to determine the
effect on the overall estimate. The estimates changed quite little,
strengthening the results from this meta-analysis. Heterogeneity,
however, still existed when each study was excluded in the
sensitivity analysis, which indicated that population selection,
cancer type and particular study were not the source of
heterogeneity. Variability in frequency of this TNF-a-238
polymorphism among the populations or some unknown factors
may be the source of heterogeneity. No publication bias was
shown also suggesting this possible true result.
Several potential factors must be concerned with respects to the
null association between TNF-a-238 polymorphism and cancers.
First, cancer is a multi-factorial disease resulting from complex
interactions between environmental and genetic factors [22]. It is
possible that variants at this locus may have modest risks on
cancers. Some environmental factors, however, may predominate
in the development of cancer, such as living habits and exposure to
carcinogens. Without considering these factors, it may lead to the
failure to detect the role of TNF-a-238 polymorphism in cancer
development. Second, some single-nucleotide polymorphisms of
some cytokines, such as polymorphisms of interleukin-8-251,
interleukin-10-819, transforming growth factor beta1-509 and
TNF-a-308, may exert their complex and interacting functions
with each other, which could affect the effects of TNF-a-238
polymorphism in the pathogenesis of cancer. Therefore, other
polymorphisms as cancer risk factors should be taken into account
to conclude a true effect. Third, this polymorphism might have
Table 1. Results of pooled ORs in the meta-analysis.
Group N Case/control OR (95% CI) P
Overall 34 34679/41186 1.09(0.88,1.34) 0.42
Cancer type
Gastric 9 1447/2633 1.22(0.88,1.70) 0.23
Breast 3 28443/29463 1.13(0.77,1.67) 0.52
Hepatocellular 4 500/667 1.44(0.82,2.52) 0.21
Others 18 4289/8423 0.99(0.66,1.50) 0.97
Ethnicity
Caucasian 16 32165/38090 1.14(0.91,1.43) 0.27
Asian 18 2514/3096 0.97(0.58,1.61) 0.89
doi:10.1371/journal.pone.0022092.t001
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interleukin-6-174CC genotype was a risk factor on bladder cancer
while tends to be a protector on colorectal cancer and gastric caner
[43]. However, the number of current studies of some particular
cancer types is small, which means further investigations involving
more cancer types are needed. Forth, TNF-a-308 polymorphism is
significantly linked with higher occurrences of TNF-a-producing
autoimmune Major Histocompatibility Complex (MHC) haplo-
type HLA-A1, B8, DR3, which was already confirmed as a risk
factor for cancers [44]. However, it is still unknown whether TNF-
a-238 polymorphism relates to MHC haplotype, which needs
more investigation in the future. Thus, the lack of counting those
factors above may affect the conclusions. This meta-analysis has
pooled the available data from the case-control studies, which
significantly increased statistical power. It cannot, however,
overcome the above potentially critical factors.
In conclusion, no significant association was detected between
TNF-a-238 polymorphism and cancers in this meta-analysis. Since
the eligible case-control studies cannot provide a causal associa-
tion, large well-designed cohort studies in the susceptibility of
Figure 1. ORs and 95% confidence interval (CI) of cancer according to TNF-a-238 polymorphism in 34 studies using random-effect
model. AA+GA, AA and GA genotypes of TNF-a-238 polymorphism; GG, GG genotype of TNF-a-238 polymorphism; ORs, odds ratios.
doi:10.1371/journal.pone.0022092.g001
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future.
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